

MARKET REPORT



Acne vulgaris- Epidemiology Insights to 2023

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Acne vulgaris- Epidemiology Insights to 2023

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Acne vulgaris- Epidemiology Insights to 2023

DelveInsight's "Acne Vulgaris (AV) - Epidemiology Insights-2023" Report provides an overview of the disease, historical and forecasted epidemiological data for the Diagnosed cases of Acne Vulgaris (AV) from 2013-2023 for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan.

Acne vulgaris is a common chronic skin disease/disorder of pilosebaceous follicles. The disease is characterized by blockage and/or inflammation of hair follicles and their accompanying sebaceous gland. Acne develops in regions of high sebaceous gland. The disease is seen to occur mostly in adolescence. At puberty androgens due to the increase in sebum production from enlarged sebaceous glands, the glands become blocked. Propionibacterium acnes further colonise and lead to lesion production although its exact role is unclear.

According to DelveInsight, based on the secondary sources and key opinion leaders (KOLs) the Diagnosed cases of Acne Vulgaris (AV) are increasing at the CAGR of XXXX% during the forecast period 2013-2023. The number of diagnosed Acne vulgaris cases in 7 major markets is expected to reach approximately 138 Million cases in 2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

The report will help in developing business strategies by understanding the trends shaping and driving the Acne Vulgaris (AV) market.

The Report covers the detailed historical and forecasted Acne Vulgaris (AV) epidemiology cases covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.

Acne vulgaris Disease Overview

Acne vulgaris Prevalence

Acne vulgaris Incidence

Acne vulgaris Risk Factors

Acne vulgaris Epidemiology

Acne vulgaris Patient Populations

Acne vulgaris Diagnosed Patients

Acne vulgaris Forecast

Acne vulgaris Epidemiology Forecast

Acne vulgaris Treated patients/population

Additional Details

Publisher : Delve Insight

Reference : DIEI0003

Number of Pages : 40

Report Format : PDF

Publisher Information :

The advertisement features a person in a white lab coat and blue gloves holding a report cover. The report cover displays the DelveInsight logo, a cityscape, and the BioPortfolio title. The background is a laboratory setting with test tubes and a pipette.

DELVEINSIGHT
INSIGHTS DRUGS PATENTS & DATA

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Table Of Contents for Acne vulgaris- Epidemiology Insights to 2023 [Report Updated: 01-01-2017]

- Report IntroductionAcne VulgarisOverviewSigns and symptomsTypes of AcnePathophysiologyDiagnosisEpidemiology and Patient PopulationTotal Number of cases- Geography wise- 2016Total Number of cases- Geography wise- 2023Total Number of cases- 7MM - 2016Total Number of cases- 7MM - 2023United StatesDiagnosed Cases of Acne Vulgaris in United StatesGermanyDiagnosed Cases of Acne Vulgaris in GermanyFranceDiagnosed Cases of Acne Vulgaris in FranceUnited KingdomDiagnosed Cases of Acne Vulgaris in United KingdomSpainDiagnosed Cases of Acne Vulgaris in SpainItalyDiagnosed Cases of Acne Vulgaris in ItalyJapanDiagnosed Cases of Acne Vulgaris in JapanAppendixReport MethodologyConsulting ServicesDisclaimerAbout DelveInsight

List Of Tables in Acne vulgaris- Epidemiology Insights to 2023 [Report Updated: 01-01-2017]

Table 1: Total Number of cases- Geography wise- 2016

Table 2: Total Number of cases- Geography wise- 2023

Table 3: Total Number of cases- 7MM - 2016

Table 4: Total Number of cases- 7MM - 2023

Table 5: Diagnosed Cases Acne Vulgaris in United States (2013-2023)

Table 6: Diagnosed Cases Acne Vulgaris in Germany (2013-2023)

Table 7: Diagnosed Cases Acne Vulgaris in France (2013-2023)

Table 8: Diagnosed Cases Acne Vulgaris in United Kingdom (2013-2023)

Table 9: Diagnosed Cases Acne Vulgaris in Spain (2013-2023)

Table 10: Diagnosed Cases Acne Vulgaris in Italy (2013-2023)

Table 11: Diagnosed Cases Acne Vulgaris in Japan (2013-2023)

List Of Figures, Charts and Diagrams in Acne vulgaris- Epidemiology Insights to 2023 [Report Updated: 01-0-2017]

Figure 1: Cellular mechanisms hypothesized to govern the pathogenesis of Acne Vulgaris

Figure 2: Total Number of cases- Geography wise- 2016

Figure 3: Total Number of cases- Geography wise- 2023

Figure 4: Total Number of cases- 7MM - 2016

Figure 5: Total Number of cases- 7MM - 2023

Figure 6: Diagnosed Cases of Acne Vulgaris in United States (2013-2023)

Figure 7: Diagnosed Cases of Acne Vulgaris in Germany (2013-2023)

Figure 8: Diagnosed Cases of Acne Vulgaris in France (2013-2023)

Figure 9: Diagnosed Cases of Acne Vulgaris in United Kingdom (2013-2023)

Figure 10: Diagnosed Cases of Acne Vulgaris in Spain (2013-2023)

Figure 11: Diagnosed Cases of Acne Vulgaris in Italy (2013-2023)

Figure 12: Diagnosed Cases of Acne Vulgaris in Japan (2013-2023)

How to Buy...

Acne vulgaris- Epidemiology Insights to 2023 [Report Updated: 01-01-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/105447>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2750** | Single User Price
- \$5500** | Site License Price
- \$8250** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.